Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.71)
# 3,116
Out of 4,667 analysts
59
Total ratings
25%
Success rate
-29.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $3.18 | +497.48% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $8.24 | +154.85% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $1.37 | +264.96% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $6.50 | +146.15% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $10 | $2.29 | +336.68% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $18.92 | +32.14% | 2 | May 14, 2024 | |
| ALRN Aileron Therapeutics | Maintains: Buy | $9 → $19 | $2.76 | +588.41% | 2 | Apr 18, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $0.49 | - | 3 | Mar 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $200 | $3.85 | +5,094.81% | 1 | Feb 8, 2024 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $7 | $1.57 | +345.86% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $2.90 | +244.83% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3 | $0.19 | +1,448.79% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $0.44 | +1,263.64% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.05 | +852.38% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $2.44 | +9,736.07% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $14 | $0.90 | +1,458.33% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.91 | +8,691.21% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $6.17 | +224.15% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $2.40 | +1,900.00% | 1 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.30 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.19 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.52 | +294.74% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $5.07 | +314.20% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $300 | $0.63 | +47,853.96% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $6.54 | +465.75% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $20 | $1.00 | +1,900.00% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $743.35 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $71.05 | +25.26% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $123.29 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $1,000 | $1.40 | +71,328.57% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $3.97 | +8,363.48% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $5.36 | +235.82% | 1 | Mar 19, 2020 |
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $3.18
Upside: +497.48%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $8.24
Upside: +154.85%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $1.37
Upside: +264.96%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $6.50
Upside: +146.15%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $10
Current: $2.29
Upside: +336.68%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $18.92
Upside: +32.14%
Aileron Therapeutics
Apr 18, 2024
Maintains: Buy
Price Target: $9 → $19
Current: $2.76
Upside: +588.41%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.49
Upside: -
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $200
Current: $3.85
Upside: +5,094.81%
PMV Pharmaceuticals
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.57
Upside: +345.86%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $2.90
Upside: +244.83%
Sep 22, 2023
Initiates: Buy
Price Target: $3
Current: $0.19
Upside: +1,448.79%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $0.44
Upside: +1,263.64%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $1.05
Upside: +852.38%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $2.44
Upside: +9,736.07%
Apr 28, 2023
Maintains: Buy
Price Target: $8 → $14
Current: $0.90
Upside: +1,458.33%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.91
Upside: +8,691.21%
Mar 7, 2023
Initiates: Buy
Price Target: $20
Current: $6.17
Upside: +224.15%
Dec 7, 2022
Initiates: Buy
Price Target: $48
Current: $2.40
Upside: +1,900.00%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.30
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.19
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $1.52
Upside: +294.74%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $5.07
Upside: +314.20%
May 6, 2022
Initiates: Buy
Price Target: $300
Current: $0.63
Upside: +47,853.96%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $6.54
Upside: +465.75%
Nov 8, 2021
Upgrades: Buy
Price Target: $20
Current: $1.00
Upside: +1,900.00%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $743.35
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $71.05
Upside: +25.26%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $123.29
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $1,000
Current: $1.40
Upside: +71,328.57%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $3.97
Upside: +8,363.48%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $5.36
Upside: +235.82%